Researchers unveiled a programmable RNA engineering platform designed to restore major histocompatibility complex class I (MHC-I) expression, aiming to improve immune recognition in immune-resistant tumors such as prostate cancer. The approach uses precise manipulation of mRNA alternative polyadenylation (APA) to reinstate antigen presentation machinery. The study’s central claim is that the engineered RNA strategy can “reprogram” tumor cells to become more visible to T cells, addressing a key bottleneck in checkpoint immunotherapy—insufficient tumor antigen presentation. For biotech pipeline builders, the headline risk-and-reward is delivery and durability: programmable RNA strategies depend on consistent expression and target engagement in vivo, but the mechanism is immediately relevant for combination design with checkpoint inhibitors.